Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.

Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodríguez C, Imaz A, Espinosa N, García-Bujalance S, Pérez-Elías MJ, García-Alvarez M, Iribarren JA, Santos J, Dalmau D, Aguilera A, Vinuesa D, Gutiérrez F, Piérola B, Molina JM, Peraire J, Portilla I, Gómez-Sirvent JL, Olalla J, Galera C, Blanco JR, Riera M, García-Fraile L, Navarro G, Curran A, Poveda E, García F; CoRIS .

J Antimicrob Chemother. 2019 Mar 5. pii: dkz067. doi: 10.1093/jac/dkz067. [Epub ahead of print]

PMID:
30838386
2.

Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.

Navarro J, Santos JR, Silva A, Burgos J, Falcó V, Ribera E, Imaz A, Curran A.

Pharmacotherapy. 2019 Feb 5. doi: 10.1002/phar.2227. [Epub ahead of print]

PMID:
30723941
3.

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).

Imaz A, Niubó J, Cottrell ML, Perez E, Kashuba ADM, Tiraboschi JM, Morenilla S, Garcia B, Podzamczer D.

Clin Infect Dis. 2018 Dec 18. doi: 10.1093/cid/ciy1074. [Epub ahead of print]

PMID:
30561517
4.

Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant.

Perales C, Chen Q, Soria ME, Gregori J, Garcia-Cehic D, Nieto-Aponte L, Castells L, Imaz A, Llorens-Revull M, Domingo E, Buti M, Esteban JI, Rodriguez-Frias F, Quer J.

Infect Drug Resist. 2018 Nov 8;11:2207-2210. doi: 10.2147/IDR.S172226. eCollection 2018.

5.

Changes in Body Fat Distribution in Antiretroviral-Naive HIV-Positive Individuals Initiating Current ART Regimens.

Tiraboschi J, Navarro-Alcaraz A, Giralt D, Gomez-Vaquero C, Saumoy M, Imaz A, Podzamczer D.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):900-905. doi: 10.1210/jc.2018-01489.

PMID:
30371793
6.

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.

Pasquau J, Hidalgo-Tenorio C, Montes ML, Romero-Palacios A, Vergas J, Sanjoaquín I, Hernández-Quero J, Aguirrebengoa K, Orihuela F, Imaz A, Ríos-Villegas MJ, Flores J, Fariñas MC, Vázquez P, Galindo MJ, García-Mercé I, Lozano F, de Los Santos I, de Jesus SE, García-Vallecillos C; QoLKAMON STUDY GROUP.

PLoS One. 2018 Apr 12;13(4):e0195068. doi: 10.1371/journal.pone.0195068. eCollection 2018.

7.

Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment.

Bernal E, Gómez JM, Jarrín I, Cano A, Muñoz A, Alcaraz A, Imaz A, Iribarren JA, Rivero M, Arazo P, Gutiérrez F; CoRIS Study Group.

J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):329-337. doi: 10.1097/QAI.0000000000001678.

PMID:
29543636
8.

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).

Imaz A, Niubó J, Amara A, Khoo S, Ferrer E, Tiraboschi JM, Acerete L, Garcia B, Vila A, Podzamczer D.

J Neurovirol. 2018 Aug;24(4):391-397. doi: 10.1007/s13365-018-0626-4. Epub 2018 Mar 14.

PMID:
29542028
9.

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Jun;24(3):388-389. doi: 10.1007/s13365-017-0613-1.

PMID:
29318452
10.

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Feb;24(1):98-105. doi: 10.1007/s13365-017-0600-6. Epub 2017 Dec 26. Erratum in: J Neurovirol. 2018 Jan 9;:.

PMID:
29280108
11.

Extracutaneous atypical syphilis in HIV-infected patients.

Prieto P, Imaz A, Calatayud L, García O, Saumoy M, Podzamczer D.

Med Clin (Barc). 2017 Dec 7;149(11):488-492. doi: 10.1016/j.medcli.2017.06.006. Epub 2017 Jul 22. English, Spanish.

PMID:
28739269
12.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.

13.

Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.

Imaz A, Podzamczer D.

Expert Rev Anti Infect Ther. 2017 Mar;15(3):195-209. doi: 10.1080/14787210.2017.1286736. Epub 2017 Feb 8.

PMID:
28117606
14.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R; PROTEST study group.

HIV Med. 2017 Aug;18(7):482-489. doi: 10.1111/hiv.12479. Epub 2016 Dec 30.

PMID:
28035758
15.

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D.

J Infect Dis. 2016 Nov 15;214(10):1512-1519. Epub 2016 Aug 30.

16.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184.

17.

Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components.

Llibre JM, de Lazzari E, Molina JM, Gallien S, Gonzalez-García J, Imaz A, Podzamczer D, Clotet B, Domingo P, Gatell JM.

Enferm Infecc Microbiol Clin. 2018 Jan;36(1):16-20. doi: 10.1016/j.eimc.2016.07.006. Epub 2016 Aug 29. English, Spanish.

PMID:
27595183
18.

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.

Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E.

J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. Epub 2016 Sep 2.

PMID:
27591292
19.

Elvitegravir concentrations in seminal plasma in HIV-1-infected men.

Imaz A, Niubó J, Kashuba AD, Ferrer E, Sykes C, Rozas N, Acerete L, Vila A, Podzamczer D.

HIV Med. 2017 Mar;18(3):225-230. doi: 10.1111/hiv.12417. Epub 2016 Aug 1.

20.

Dual antiretroviral therapy: finding a place in the battle.

Podzamczer D, Imaz A.

Lancet HIV. 2016 Aug;3(8):e335-e336. doi: 10.1016/S2352-3018(16)30021-2. Epub 2016 May 31. No abstract available.

PMID:
27470021

Supplemental Content

Loading ...
Support Center